|
AstraZeneca PLC and Merck & Co Inc on Wednesday said their jointly-developed Lynparza drug reduces the risk of death in a form of breast cancer.
In data presented on Wednesday, the duo found Lynparza reduces the risk of death by 32% versus a placebo in sufferers of high-risk human epidermal growth factor receptor 2-negative early breast cancer.
HER2 cancer means the cancerous cells do not contain the HER2 protein, which helps cells grow quicker.
In addition, Lynparza improved the three-year survival rate to just under 93% from just over 89% in those taking a placebo.
At four years, the survival rate for those on Lynparza was just under 90%, versus just over 86% in the placebo.
AstraZeneca shares closed 0.4% higher at 9,416.00 pence each in London on Wednesday.
Merck & Co fell 1.1% to $77.75 in New York.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
